ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1478 National Cancer Institute Html en Skin Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of skin cancer.
treatment0.409923
metastatic basal cell0.400394
subsequent basal cell0.391984
Skin Cancer Prevention0.365074
Arch Dermatol0.471327
photodynamic therapy0.399886
sun-exposed skin0.375699
skin cancers0.433811
primary skin cancers0.370681
uncomplicated basal cell0.398522
basal-cell carcinoma0.373761
PUBMED Abstract0.376972
Mohs micrographic surgery0.406259
Invest Dermatol0.363857
prior skin cancer0.363746
multiple basal cell0.397256
nonmelanoma skin cancers0.400983
recurrence rates0.396208
Dermatol Surg Oncol0.421496
periocular basal cell0.39808
BCC0.370104
Abstract0.389392
main skin cancer0.382703
basal cell nevus0.404293
squamous cell carcinomas0.385705
eyelid addresses carcinomas0.365517
non-eyelid skin cancers0.367643
surgical excision0.369879
Br J Dermatol0.407426
cosmetic results0.379562
superficial basal cell0.487048
skin cancer awareness0.383438
basal cell carcinomas0.527823
nodular skin BCCs0.369486
nodular basal cell0.432753
nonmelanoma skin cancers.0.373768
nevoid Basal cell0.396437
primary superficial basal0.391239
radiation therapy0.475907
nonmelanoma skin cancer0.483068
basal cell carcinoma0.980145
regional lymph nodes0.369237
radiation therapy treatment0.376744
longstanding skin ulcers0.361677
et al.0.442813
Acad Dermatol0.422124
squamous cell carcinoma0.41423
CLICK HERE
1541 National Cancer Institute Html en Testicular Cancer Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of testicular cancer.
tumor marker levels0.613741
cancer treatment0.320393
testicle0.4399
testicular cancer spreads0.297436
contains cancer cells0.273957
body0.340237
PDQ cancer information0.333395
testicular cancer0.725943
testicular germ cell0.272075
clinical trial search0.331245
long-term follow-up0.27959
clinical trials0.622305
undescended testicle0.275057
cancer information summary0.310365
clinical trial0.428741
spermatic cord0.329024
tumor markers0.368096
inguinal orchiectomy0.361937
patients0.336056
malignant tumor cells0.300585
NCI PDQ cancer0.275949
lymph nodes0.529321
radiation therapy0.376906
Serum tumor marker0.305709
general cancer information0.270473
treatment0.469864
general information0.294195
NCI-supported cancer0.288405
cancer cells0.405185
Recurrent testicular cancer0.320003
Cancer Information Service0.271409
treatment clinical trials0.292646
National Cancer Institute0.350045
lymph vessels0.288149
new treatment0.293694
distant lymph nodes0.317031
combination chemotherapy0.304741
Testicular Cancer Treatment0.305239
metastatic tumor0.2721
blood0.282323
tumor marker test0.304459
retroperitoneal lymph nodes0.28218
cancer clinical trials0.344359
stage0.329917
testicular tumor0.289398
comprehensive cancer information0.269733
cancer0.908321
information0.339805
following tumor markers0.277178
CLICK HERE
1688 National Cancer Institute Html en Cannabis and Cannabinoids (PDQ®)–Patient Version Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting.
cancer treatment0.54874
PDQ Cannabis0.53541
PDQ cancer information0.561631
Cancer Complementary0.483651
cancer therapy0.493942
clinical trials0.738523
cannabinoid receptors0.573547
advanced cancer patients0.489779
U.S. Food0.49892
cancer information summary0.529639
National Institutes0.485607
alternative cancer therapies0.482187
clinical trial0.556349
cancer therapies0.496308
patients0.580973
cancer patients0.559766
Cannabis users0.54158
Investigational New Drug0.490753
NCI PDQ cancer0.493719
cancer information database0.48226
effects0.498728
cannabinoids0.769857
main active cannabinoid0.509915
treatment0.563891
breast cancer cells0.497802
Cannabis plant extract0.540785
United States0.581783
Cannabis plant0.559258
Complementary Therapies Editorial0.487662
Drug Administration0.596753
Cancer Information Specialist0.479354
cancer cells0.516435
Cancer Information Service0.529301
Cannabis extract0.551963
National Cancer Institute0.60295
studies0.507275
alternative medicine0.50524
pain relief0.516491
advanced cancer0.497262
approved research settings0.478938
cannabis0.903862
chemotherapy-related nausea0.514076
cancer cell death0.500487
medicinal Cannabis0.540165
cancer clinical trials0.488981
alternative therapies0.483937
cancer information summaries0.482387
cancer0.807964
CLICK HERE
1741 National Cancer Institute Html en Menopausal Hormone Therapy and Cancer A fact sheet about the results of research on menopausal hormone therapy (MHT). Includes information about the effect of MHT on the body and benefits and risks of using menopausal hormones.
M. Menopausal hormone0.399446
estrogen0.661955
progestin0.473666
menopausal symptoms0.433158
lung cancer0.436349
postmenopausal estrogen0.401234
Anderson GL0.391175
Breast Cancer Research0.404812
MHT0.573747
placebo0.469804
whi estrogen-plus-progestin study0.43139
colorectal cancer0.510049
breast cancer survivors0.442442
vertebral fractures0.396082
hormone therapy group0.403745
hormone therapy medication0.406528
hot flashes0.474358
invasive breast cancer0.436727
hormone replacement therapy0.391432
Health Initiative0.489409
randomized clinical trials0.471592
menopausal hormone therapy0.725067
WHI trials0.489874
health effects0.386028
women0.908896
MHT change0.392923
breast cancer detection0.43656
Non-FDA-approved hormone products0.402601
One-third lower risk0.39906
breast cancer recurrence0.408176
breast cancers0.398762
estrogen-alone MHT0.393357
10,000 women0.558208
National Cancer Institute0.442573
natural hormones estrogen0.458568
hormone therapy0.86696
combined hormone therapy0.473354
postmenopausal women0.502051
absolute terms0.40498
breast cancer0.990788
WHI Estrogen-Alone Study0.441842
Chlebowski RT0.451885
randomized controlled trial0.389145
healthy postmenopausal women0.397371
et al0.576891
New England Journal0.390547
breast cancer incidence0.436953
Women’s Health0.429633
risk0.448458
CLICK HERE
1894 National Cancer Institute Html es Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas.
radiocirugía estereotáctica0.521736
cuáles ganglios0.544229
estadio iv0.535294
pequeño corte0.516426
sustancia llamada fcev0.511226
faja ajustadora0.518847
pequeña cantidad0.570347
Silbido respiratorio0.522024
cáncer.ampliar broncoscopia0.521373
gen alk0.51503
cáncer.ampliar mediastinoscopía0.517089
células normales.ampliar exploración0.600106
cuerpo.ampliar radiografía0.522592
estadios ia0.514018
rayos x0.552576
estadio ib0.557189
estadio ia0.556394
enlace drugs approved0.531609
ondas sonoras0.51647
Non-Small Cell Lung0.531866
células t0.528626
vías respiratorias0.808836
carcinoma epidermoide0.525518
numerosos ensayos0.516625
pecho.ampliar biopsia0.526618
estadios iia0.515213
estadio iiia0.625519
determinadas células0.530359
antecedentes familiares0.518918
alta potencia0.516655
estadio iia0.557019
tirosina cinasa0.692486
Cell Lung Cancer0.531364
siguientes sitios0.51534
siguientes situaciones0.666362
ecografía ayuda0.515534
principal factor0.576142
áreas.ampliar biopsia0.52208
siguientes formas0.529859
bronquiolos.ampliar anatomía0.52368
siguientes sumarios0.532291
siguientes pruebas0.527678
vasos sanguíneos0.979174
CLICK HERE
1951 National Cancer Institute Html es Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos.
siguientes procedimientos0.408317
displasia multilinaje0.404818
células madre0.698581
leucemia aguda0.40611
síndromes mielodisplásicos0.99284
hueso compacto0.416921
neoplasias mieloides0.402645
plaquetas maduras0.410918
célula madre mieloide0.437557
National Cancer Institute0.402744
siguientes riesgos0.401921
vitamina b120.403995
Instituto Nacional0.404912
PDQ Tratamiento0.439829
célula madre linfoide0.43173
vidrio piezas0.403146
neoplasias mielodisplásicas0.404775
displasia unilinaje0.404747
Physician Data Query0.410747
cáncer.ampliar trasplante0.403337
leucemia mieloide aguda0.59748
célula madre0.50311
células sanguíneas maduras0.465531
siguientes pruebas0.40454
CLICK HERE
2025 National Cancer Institute Html es Exámenes de detección del cáncer colorrectal (PDQ®)–Versión para pacientes Sumario de información revisada por expertos sobre las pruebas que se usan para detectar el cáncer colorrectal.
PDQ Exámenes0.849253
Physician Data Query0.949845
sigmoidoscopia causa0.801378
tubo recolector0.784476
Estados Unidos0.979222
riesgos.Los exámenes0.85829
cuerpo).ampliar anatomía0.797555
prevención revisa0.744583
radiografías llamada0.774966
PDQ Prevención0.956837
pequeño aumento0.790999
siguientes exámenes0.980519
información ayuda0.751125
National Cancer Institute0.760892
siguientes riesgos0.742979
siguientes sumarios0.885224
Instituto Nacional0.814155
CLICK HERE
3651 National Cancer Institute Html en TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.
adjuvant chemotherapy0.787463
higher recurrence scores0.454387
21-gene recurrence score0.676351
mid-range score0.364833
postsurgical chemotherapy0.404675
Jo Anne Zujewski0.399515
Cancer Therapy Evaluation0.426635
National Clinical Trials0.404942
adult cancer research0.415943
early-stage breast cancer0.44803
Montefiore Medical Center0.406438
test’s ability0.364803
lowest 21-gene recurrence0.476043
patients0.383684
5-year recurrence rates0.497417
Trial Assigning Individualized0.434763
hormone receptor-positive breast0.606376
gene panel test0.401972
high risk0.363068
primary breast cancers0.421261
women0.592588
low risk0.421557
United States0.429126
ECOG-ACRIN Research Group0.402947
low-risk subset0.454616
breast cancer recurrence0.516723
percent0.443551
Initial findings0.364086
hormone receptor-positive disease0.474523
10,000 women0.389687
molecular test0.368711
21-gene panel test0.405027
various treatment options0.412166
hormone therapy0.89376
aromatase inhibitor therapy0.427967
primary cancer events0.412638
NCIC-Clinical Trials Group0.404753
postoperative treatment0.371444
estrogen receptor0.368053
early-stage hormone0.432936
breast cancer0.917923
21-gene recurrence test0.48221
Recurrence events0.412295
breast cancer mortality0.453698
-positive breast cancer0.464645
New England Journal0.424409
HER2-negative breast cancer0.446932
journal article0.367547
CLICK HERE
16693 National Cancer Institute Html en In an Era of Precision Medicine, Testing New Approaches to Breast Cancer Screening An NCI research article about individualized approaches that could help identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk.
clinical DNA testing0.255296
certain genetic alterations0.26295
Family Comprehensive Cancer0.304528
early molecular changes0.250583
Breast Cancer Surveillance0.393407
Dr. Szabo0.324259
Breast Care Center0.362601
ovarian cancer patients0.316413
clinical trial0.331236
breast cancer prevention0.392842
breast density0.431317
annual mammography0.280302
risk-based group0.308284
breast MRI0.280239
Dr. Tice0.272786
molecular changes0.271002
seminal clinical trials0.251623
Consortium Risk Calculator0.280953
risk-based approach0.302169
high risk0.287254
precision medicine0.358439
genetic markers0.26055
women0.30866
risk-based screening arm0.644595
annual mammograms0.27926
hereditary breast0.275314
cancer screening0.642713
cancer prevention0.415329
HBOC—for genetic alterations0.253144
risk-based screening strategies0.470957
advanced-stage breast cancers0.351274
family medical history0.264412
General Internal Medicine0.258705
Cancer MoonshotSM Blue0.314025
risk-based screening0.987559
false-positive test results0.2742
lowest risk scores0.302649
strongest risk factor0.279896
breast cancer risk0.568335
screening interval0.333337
breast cancer0.836019
genetic alterations0.266377
annual screening group0.404487
risk factor0.298033
precision cancer prevention0.325999
risk prediction model0.28587
WISDOM trial0.343878
highest risk scores0.301801
ovarian cancer syndrome0.315021
CLICK HERE
16829 National Cancer Institute Html en Cancer Driver Discovery Program null
large number0.638311
tumor biology0.66038
rare driver events0.719635
comprehensive genomic characterization0.740363
genomic analyses0.633135
patient responses0.721865
tumor tissues0.638276
additional driver mutations0.771411
lung cancer0.952268
statistical models0.628862
statistical power0.629897
cancer genomics0.65394
recurrent mutations0.655852
patients0.702611
Genomic Data Commons0.762952
clinical trial N01470.722969
Lung Cancer project0.792668
molecular causes0.642033
oncogenic process0.640394
public health impact0.739202
epidermal growth factor0.708102
tumor types0.658904
Cancer Driver Discovery0.8155
DNA sequencing0.651327
Cancer Research UK0.776689
RNA sequence0.636519
associated follow-up information0.721592
ovarian cancers0.639935
better treatment options0.776737
clinical outcomes0.638824
Foundation Lung Cancer0.793933
intratumoral heterogeneity0.742723
deeper characterization0.652385
TRACERx collaborators0.637079
NCI-funded clinical trial0.73112
Genome Characterization Pipeline0.748856
driver mutations0.919706
St. James0.824605
Tracking Cancer Evolution0.775958
CCG0.851349
colon cancer0.744767
lung adenocarcinoma0.669686
TRACERx study0.634122
total RNA sequencing0.961331
Cancer Genome Atlas0.832019
chemotherapy regimen0.639583
particular lung cancer0.807795
Central Cancer Treatment0.762707
genome sequencing0.685209
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.